BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 10936358)

  • 21. The regulation of the complement system: insights from genetically-engineered mice.
    Turnberg D; Botto M
    Mol Immunol; 2003 Sep; 40(2-4):145-53. PubMed ID: 12914820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complement-regulatory proteins in ovarian malignancies.
    Bjørge L; Hakulinen J; Wahlström T; Matre R; Meri S
    Int J Cancer; 1997 Jan; 70(1):14-25. PubMed ID: 8985085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A study of human DAF, CD59, MCP transgene in xenotransplantation.
    Chen S; Chen G; Cai CC; Wang XM; Guo H; Shen SQ; Wang H; Wu Y; Li GX; Huang J; Li WX; Wei QX; Sun FZ
    Transplant Proc; 2001; 33(7-8):3851-2. PubMed ID: 11750639
    [No Abstract]   [Full Text] [Related]  

  • 24. Upregulation of complement regulators MCP (CD46), DAF (CD55) and protectin (CD59) in arthritic joint disease.
    Davies ME; Horner A; Loveland BE; McKenzie IF
    Scand J Rheumatol; 1994; 23(6):316-21. PubMed ID: 7528443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition.
    Mason JC; Yarwood H; Sugars K; Morgan BP; Davies KA; Haskard DO
    Blood; 1999 Sep; 94(5):1673-82. PubMed ID: 10477692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Membrane complement regulatory proteins in autoimmune and inflammatory tissue injury.
    Song WC
    Curr Dir Autoimmun; 2004; 7():181-99. PubMed ID: 14719381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protection of xenogeneic cardiac endothelium from human complement by expression of CD59 or DAF in transgenic mice.
    Byrne GW; McCurry KR; Kagan D; Quinn C; Martin MJ; Platt JL; Logan JS
    Transplantation; 1995 Nov; 60(10):1149-56. PubMed ID: 7482724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Production and characterization of a pig line transgenic for human membrane cofactor protein.
    Zhou CY; McInnes E; Parsons N; Langford G; Lancaster R; Richards A; Pino-Chavez G; Dos Santos Cruz G; Copeman L; Carrington C; Thompson S
    Xenotransplantation; 2002 May; 9(3):183-90. PubMed ID: 11983016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Localization of the complement membrane attack complex inhibitor (CD59) in human conjunctiva and lacrimal gland.
    Bardenstein DS; Dietz Y; Lass JH; Medof ME
    Curr Eye Res; 1994 Dec; 13(12):851-5. PubMed ID: 7536649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of membrane-bound complement regulatory proteins in prostate cancer.
    Loberg RD; Wojno KJ; Day LL; Pienta KJ
    Urology; 2005 Dec; 66(6):1321-6. PubMed ID: 16360477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune evasion of tumor cells using membrane-bound complement regulatory proteins.
    Gorter A; Meri S
    Immunol Today; 1999 Dec; 20(12):576-82. PubMed ID: 10562709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complement-binding proteins are strongly expressed by human preimplantation blastocysts and cumulus cells as well as gametes.
    Taylor CT; Johnson PM
    Mol Hum Reprod; 1996 Jan; 2(1):52-9. PubMed ID: 9238658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levels of complement regulatory molecules in lung cancer: disappearance of the D17 epitope of CD55 in small-cell carcinoma.
    Sakuma T; Kodama K; Hara T; Eshita Y; Shibata N; Matsumoto M; Seya T; Mori Y
    Jpn J Cancer Res; 1993 Jul; 84(7):753-9. PubMed ID: 7690355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distribution of complement regulators (CD46, CD55 and CD59) in skin appendages, and in benign and malignant skin neoplasms.
    Sayama K; Shiraishi S; Miki Y
    Br J Dermatol; 1992 Jul; 127(1):1-4. PubMed ID: 1379063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are pigs transgenic for human complement regulatory proteins necessary for xenotransplantation?
    Loveland BE; Cooper DK; Sandrin MS
    Transplantation; 2000 Aug; 70(4):567-8. PubMed ID: 10972209
    [No Abstract]   [Full Text] [Related]  

  • 36. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance.
    Varsano S; Rashkovsky L; Shapiro H; Ophir D; Mark-Bentankur T
    Clin Exp Immunol; 1998 Aug; 113(2):173-82. PubMed ID: 9717965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of transfected MACIF (CD59) on complement-mediated swine endothelial cell lysis, compared with those of membrane cofactor protein (CD46) and decay-accelerating factor (CD55).
    Miyagawa S; Shirakura R; Nakata S; Izutani H; Matsuda H; Iwata K; Nagasawa S; Terado A; Hatanaka M; Matsumoto M
    Transplant Proc; 1995 Feb; 27(1):328-9. PubMed ID: 7533401
    [No Abstract]   [Full Text] [Related]  

  • 38. Human regulator of complement activation (RCA) gene family proteins and their relationship to microbial infection.
    Seya T
    Microbiol Immunol; 1995; 39(5):295-305. PubMed ID: 7565169
    [No Abstract]   [Full Text] [Related]  

  • 39. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis.
    Brooimans RA; van Wieringen PA; van Es LA; Daha MR
    Eur J Immunol; 1992 Dec; 22(12):3135-40. PubMed ID: 1280224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protease-modified erythrocytes: CD55 and CD59 deficient PNH-like cells.
    Yuan FF; Bryant JA; Fletcher A
    Immunol Cell Biol; 1995 Feb; 73(1):66-72. PubMed ID: 7539403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.